PatentJun 26, 2026, 07:16 AM
Can-Fite Secures Japanese Patent for Namodenoson Anti-Obesity
AI Summary
Can-Fite BioPharma Ltd. announced that the Japan Patent Office has allowed a patent for Namodenoson's anti-obesity technology. This patent covers the use of A3 adenosine receptor agonists, including Namodenoson, for fat loss and treating obesity and related metabolic disorders. This allowance significantly strengthens the company's global intellectual property portfolio in a major pharmaceutical market, complementing existing patents in other key jurisdictions and supporting future partnering opportunities for Namodenoson in the rapidly expanding obesity therapeutics market.
Key Highlights
- Japan Patent Office allowed Japanese Patent Application No. 2025-049941 for Namodenoson.
- The patent covers the use of A3 adenosine receptor agonists for inducing fat loss and treating obesity.
- This strengthens Can-Fite's global intellectual property portfolio, adding to patents in US, Canada, Australia, and Israel.
- The technology is supported by scientific evidence published in the International Journal of Obesity.
- Namodenoson is an orally administered A3AR agonist with an established safety profile.
- The global obesity therapeutics market is projected to exceed $60 billion by 2030.
Price Impact
More from CANF